These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8541245)

  • 21. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of brain imaging in assessment of cognitive symptoms. Cognitive and emotional impact of antipsychotic drug treatment]].
    Martinot JL; Peretti CS
    Encephale; 2006 Jan; 32 Pt 2():S3-5. PubMed ID: 16800076
    [No Abstract]   [Full Text] [Related]  

  • 24. Neurocognitive impairment in schizophrenia and how it affects treatment options.
    Bilder RM
    Can J Psychiatry; 1997 Apr; 42(3):255-64. PubMed ID: 9114941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2010 Mar; 8(91):19-24. PubMed ID: 20179667
    [No Abstract]   [Full Text] [Related]  

  • 26. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
    Keefe RS; Haig GM; Marder SR; Harvey PD; Dunayevich E; Medalia A; Davidson M; Lombardo I; Bowie CR; Buchanan RW; Bugarski-Kirola D; Carpenter WT; Csernansky JT; Dago PL; Durand DM; Frese FJ; Goff DC; Gold JM; Hooker CI; Kopelowicz A; Loebel A; McGurk SR; Opler LA; Pinkham AE; Stern RG
    Schizophr Bull; 2016 Jan; 42(1):19-33. PubMed ID: 26362273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

  • 28. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE
    J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison table: drugs for Alzheimer's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):e160-e161. PubMed ID: 28922344
    [No Abstract]   [Full Text] [Related]  

  • 31. May non-antipsychotic drugs improve cognition of schizophrenia patients?
    Buoli M; Altamura AC
    Pharmacopsychiatry; 2015 Mar; 48(2):41-50. PubMed ID: 25584772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. All antipsychotics are equal, but some are more equal than others.
    Volavka J; Citrome L
    J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Faragian S; Fuchs C; Pashinian A
    Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Another view of therapy for cognition in schizophrenia.
    Carpenter WT; Gold JM
    Biol Psychiatry; 2002 Jun; 51(12):969-71. PubMed ID: 12062880
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Schizophrenia, psychotropic drugs and cognition].
    Fakra E; Kaladjian A; Adida M; Cermolacce M; Belzeaux R; Azorin JM
    Encephale; 2011 Dec; 37 Suppl 2():S137-42. PubMed ID: 22212844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment.
    Chabrol H; Peresson G; Bonnet D
    Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.